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A B S T R A C T
Background
Chronic cough (a cough lasting longer than four weeks) is a common problem internationally. Chronic cough has associated economic
costs and is distressing to the child and to parents; ignoring cough may lead to delayed diagnosis and progression of serious underlying
respiratory disease. Clinical guidelines have been shown to lead to efficient and effective patient care and can facilitate clinical decision
making. Cough guidelines have been designed to facilitate the management of chronic cough. However, treatment recommendations
vary, and specific clinical pathways for the treatment of chronic cough in children are important, as causes of and treatments for
cough vary significantly from those in adults. Therefore, systematic evaluation of the use of evidence-based clinical pathways for the
management of chronic cough in children would be beneficial for clinical practice and for patient care. Use of a management algorithm
can improve clinical outcomes; such management guidelines can be found in the guidelines for cough provided by the American College
of Chest Physicians (ACCP) and the British Thoracic Society (BTS).
Objectives
To evaluate the effectiveness of using a clinical pathway in the management of children with chronic cough.
Search methods
The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE, EMBASE,
review articles and reference lists of relevant articles were searched. The latest search was conducted in January 2014.
Selection criteria
All randomised controlled trials of parallel-group design comparing use versus non-use of a clinical pathway for treatment of chronic
cough in children (< 18 years of age).
Data collection and analysis
Results of searches were reviewed against predetermined criteria for inclusion. Two review authors independently selected studies and
performed data extraction in duplicate.
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Main results
One study was included in the review. This multi-centre trial was based in five Australian hospitals and recruited 272 children with
chronic cough. Children were randomly assigned to early (two weeks) or delayed (six weeks) referral to respiratory specialists who used
a cough management pathway. When an intention-to-treat analysis was performed, clinical failure at six weeks post randomisation
(defined as < 75% improvement in cough score, or total resolution for fewer than three consecutive days) was significantly less in the
early pathway arm compared with the control arm (odds ratio (OR) 0.35, 95% confidence interval (CI) 0.21 to 0.58). These results
indicate that one additional child will be cured for every five children treated via the cough pathway (number needed to treat for an
additional beneficial outcome (NNTB) = 5, 95% CI 3 to 9) at six weeks. Cough-specific parent-reported quality of life scores were
significantly better in the early-pathway group; the mean difference (MD) between groups was 0.60 (95% CI 0.19 to 1.01). Duration
of cough post randomisation was significantly shorter in the intervention group (early-pathway arm) compared with the control group
(delayed-pathway arm) (MD -2.70 weeks, 95% CI -4.26 to -1.14).
Authors’ conclusions
Current evidence suggests that using a clinical algorithm for the management of children with chronic cough in hospital outpatient
settings is more effective than providing wait-list care. Futher high-quality randomised controlled trials are needed to perform ongoing
evaluation of cough management pathways in general practitioner and other primary care settings.
P L A I N L A N G U A G E S U M M A R Y
Clinical pathways for chronic cough in children
Background
Clinical pathways serve as a tool or algorithm (like a flow chart) that can be used in the treatment of patients with various chronic
diseases. They provide a clear guide that assists doctors in diagnosing an illness and in making decisions with the patient about what
treatment is needed or which specialists should be seen or tests ordered at each stage of progression of the disease. Overall the aim of
clinical pathways is to provide efficient care for patients. Examples of patient decision aids are provided by the National Health Service
(NHS) in the UK at http://www.rightcare.nhs.uk/index.php/shared-decision-making/about-the-pdas/.
Chronic cough in children is a significant medical problem that in some situations warrants thorough investigation. This review
examined whether using clinical pathways was effective for evaluating and managing children with chronic cough (cough lasting longer
than 4 weeks).
Study characteristics
Only a single multi-centre study could be included in this review. Evidence is current to January 2014. This study was funded by the
National Health and Medical Research Council of Australia.
Key results
This study of 272 children in five Australian hospitals reported that those randomly assigned to earlier treatment according to a clinical
pathway showed improved clinical outcomes (cough resolved earlier and quality of life was better) compared with those who were
randomly assigned to later use of the pathway. No adverse events were reported.
Quality of the evidence
The quality of evidence was graded as moderate. Evidence is limited, as only one study could be included in this review. This study
was unable to completely blind participants to the clinical pathway.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Clinical pathway compared with usual care for treatment of children with chronic cough
Patient or population: children with chronic cough of unknown origin lasting longer than 4 weeks
Settings: paediatric hospital outpatient clinics
Intervention: clinical pathway algorithm (clinical review within 2 weeks)
Comparison: usual clinical care (clinical review at 6 weeks)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard care group Clincal pathway
Clinical failure-primary
outcome (by intention-
to-treat analysis)
Follow-up: 6 weeks
71 per 100 47 per 100
(34 to 59)
OR 0.35
(0.21 to 0.58)
272
(1 study)
⊕⊕⊕©
moderatea
PC-QOL mean score at 6
weeks
PC-QOL is a 27-
item questionnaire. Each
question has a 7-point
score ranging from 1
(worst quality of life) to
7 (best quality of life).
Scores for each itemwere
added and the average
taken
5.01 (SD 1.63) 5.61
(5.2 to 6.02)
Mean difference be-
tween groups
0.60 (0.19 to 1.01)weeks
226
(1 study)
⊕⊕⊕©
moderatea
Duration of cough post
randomisation
Mean duration of cough
was 9.1 (SD 6.6) weeks
Mean duration of cough
was
6.4 (4.84 to 7.96) weeks
Mean difference be-
tween groups
-2.70 (-4.26 to -1.14)
weeks
226
(1 study)
⊕⊕⊕©
moderatea
Cough resolution was de-
fined as total resolution of
cough or≥ 75% improve-
ment in cough scores for
≥ 3 days3
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Proportion of adverse
events experienced
Follow-up: 6 months
0 per 1000 0 per 1000 Not estimable See comments ⊕⊕⊕©
moderatea
No adverse
events were reported
Proportions of partici-
pants experiencing ad-
verse events or compli-
cations
Follow-up: 6 months
0 per 1000 0 per 1000 Not estimable See comments ⊕⊕⊕©
moderatea
No adverse
events were reported
*The basis for the assumed risk was the mean control group risk in the included study. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR; Odds ratio; PC-QOL: Parent-reported cough-specific quality of life questionnaire; RR: Risk ratio; SD: Standard deviation.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aA single study was identified, and complete blinding was not possible for this type of intervention.
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B A C K G R O U N D
Description of the condition
Cough is the most common symptom presenting to primary care
internationally (Britt 1999; Cherry 2003; Irwin 2006). In Aus-
tralia, 5.8 of every 100 visits to general practitioners are result
of cough (Britt 2008). Chronic (prolonged) cough is also one of
the most common symptoms presenting to respiratory physicians
(Fitzgerald 2006). Thus, in Australia alone, these visits on a pop-
ulation level would equate to millions of dollars per year in Medi-
care rebates for general practitioner (GP) visits. Further, studies
have shown that more than 80% of children who have seen spe-
cialists for chronic cough have had more than five medical vis-
its, and over 20% had seen a doctor more than 20 times (Chang
2012; Marchant 2008). The burden of chronic cough (defined in
children as cough lasting longer than four weeks) (Chang 2006b;
Marchant 2006) is significant, both in terms of personal cost and
impaired quality of life (Marchant 2008) and at a societal level
when medication costs are substantial (Irwin 2006).
Chronic cough in children causes a significant burden of distress
for parents (Marchant 2008). Furthermore, although cough may
be seen as a merely troublesome symptom with no serious conse-
quences, ignoring cough that may be the sole presenting symptom
of an underlying respiratory disease may lead to delayed diagnosis
and progression of serious illness or chronic respiratory morbidity
(Barr 2005; Karakoc 2002). Thus for the management of chronic
cough in children, it is important for clinicians to define which
patients will benefit from which interventions and treatment ap-
proaches (including ’watchful waiting’) (Gupta 2007).
Description of the intervention
The major aim of clinical pathways or guidelines is to improve
diagnosis and/or management of the specific condition or symp-
tom. They provide a step-by-step approach for the clinician that
is based on preceding criteria. Currently, treatment recommen-
dations for cough vary among published guidelines (Irwin 2006;
Kohno 2006; Shields 2007), but none have been evaluated in
a randomised controlled trial (RCT). We (Chang 2005; Chang
2006a; Marchant 2006) and others (Shields 2006) have argued
that children with chronic cough should be evaluated and treated
in accordance with guidelines specific to children, as both causative
factors and treatment in children are significantly different from
those in adults (Chang 2006b).
How the intervention might work
Clinical guidelines have been shown to provide more efficient and
effective patient care (Fessler 2005) and, if well designed, can facili-
tate clinical decision making. This approach in turn should reduce
variations in delivery of care and delays in diagnosis or treatment
(Kwan 2004). Cough guidelines, which were first provided by Ir-
win (Irwin 1990), were designed to facilitate the management of
chronic cough. Subsequent cough guidelines have been published
by various societies.
Why it is important to do this review
Cohort studies suggest that use of cough clinical pathways or algo-
rithms improves outcomes (resolution of cough and accurate diag-
nosis) in children (Asilsoy 2008;Karabel 2013;Rehman2009) and
adults (Irwin 1990). However, use of guidelines is not universally
popular in medical circles (Preiser 2004) and may arguably result
in negative outcomes (e.g. frommissed or delayeddiagnosis). Clin-
ical guidelines are regarded by some as ’cook-book medicine,’ as
bothersome and as negating critical thinking (Berg 1997). Exam-
ination, through a systematic review, of the effectiveness of using
a clinical pathway in treating children with chronic cough would
be useful for guiding clinical practice (Elbourne 2002). This is an
update of a Cochrane review (Bailey 2004).
O B J E C T I V E S
To evaluate the effectiveness of using a clinical pathway in the
management of children with chronic cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs of parallel-group design comparing use versus non-use
of a clinical pathway for the treatment of children with chronic
cough.
Types of participants
Inclusion criteria: children (< 18 years of age) with chronic (lasting
longer than four weeks) cough of unknown origin.
Exclusion criteria: known preexisting respiratory illness causing
cough.
Types of interventions
All randomised controlled comparisons of use of a clinical path-
way. Review authors planned that trials examining use of other
medications or interventions would be included if all participants
were given equal access to such medications or interventions.
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Types of outcome measures
Primary outcomes
Proportions of participants who were not cured or were not sub-
stantially improved at follow-up (clinical failure).
Secondary outcomes
1. Proportions of participants who were not cured at follow-
up.
2. Proportions of participants who were not substantially
improved at follow-up.
3. Mean difference in cough indices (cough diary, cough
frequency, cough-specific quality of life scores, cough duration).
4. Proportions of participants experiencing adverse effects of
the intervention (e.g. Cushing’s syndrome from steroid
overdose).
5. Proportions of participants experiencing complications (e.g.
acute hospitalisations, chronic lung disease resulting from
delayed diagnosis).
Proportions of participants who failed to improve while receiving
treatment and mean clinical improvement were determined using
the following hierarchy of assessment measures (Note: When two
or more assessment measures were reported in the same study, the
outcome measure listed first in the hierarchy was used).
1. Objective measurements of cough indices (cough
frequency, cough receptor sensitivity).
2. Symptomatic assessment by participant (adult or child)
(quality of life, Likert scale, visual analogue scale, level of
interference of cough, cough diary).
3. Symptomatic assessment by parents/carers (quality of life,
Likert scale, visual analogue scale, level of interference of cough,
cough diary).
4. Symptomatic assessment by clinicians (Likert scale, visual
analogue scale, level of interference of cough, cough diary).
Search methods for identification of studies
Electronic searches
Trials were identified from the following sources.
1. The Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue 1).
2. The Cochrane Airways Group Specialised Register.
3. MEDLINE (Ovid) (1950 to January 2014).
4. EMBASE (Ovid) (1980 to January 2014).
Full search strategies are listed inAppendix 1. Conference abstracts
were handsearched and grey literature was searched through the
CENTRAL database.
Searching other resources
In addition to the electronic search, we checked the reference lists
of relevant publications and contacted the authors of the included
trial to ask for further information.
Data collection and analysis
Selection of studies
Retrieval of studies: Using article titles, abstracts or descriptors,
two review authors (EJB and ABC in original review and search
from 2009 to 2012; GBM and ABC in search from 2012 to 2014)
independently reviewed literature searches to identify potentially
relevant trials for full review. They conducted searches of bibli-
ographies and texts to identify additional studies. From the full-
text articles obtained, the same two review authors independently
assessed trials for inclusion on the basis of specific criteria. It was
planned that disagreements would be resolved by third party ad-
judication (PM), but no disagreement was reported.
Data extraction and management
We had no disagreements but had planned to resolve disagree-
ments through discussion with another review author (PSM). We
extracted data using a standardised data collection form and man-
aged them in ReviewManager 5.2, in accordance with recommen-
dations provided in the Cochrane Handbook for Systematic Review
of Interventions (Higgins 2011).When required, we requested fur-
ther information from trial authors.
Assessment of risk of bias in included studies
Two review authors (GBM and ABC) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
It was planned that disagreements would be resolved by discussion
or by third party adjudication. We assessed risk of bias according
to the following domains.
1. Allocation sequence generation (selection bias).
2. Concealment of allocation (selection bias).
3. Blinding of participants (performance bias).
4. Outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective outcome reporting (reporting bias).
Measures of treatment effect
For the dichotomous outcome variables of each individual study,
odds ratios were calculated using a modified intention-to-treat
analysis. This analysis assumes that children not available for out-
come assessment have not improved (and probably represents a
conservative estimate of effect). Other indices were assumed to
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be normally distributed continuous variables, so the mean differ-
ence in outcomes could be estimated (weighted mean difference).
It was planned that if studies reported outcomes using different
measurement scales, the standardised mean difference would be
used.
Unit of analysis issues
Cross-over trials are not appropriate for this intervention and
therefore were not planned for inclusion in any meta-analysis per-
formed. It was planned that cross-over trials that met other review
inclusion criteria would be described in the text.
Dealing with missing data
It was planned that Investigators or study sponsors would be con-
tacted to verify key study characteristics and to provide missing
numerical outcome data when necessary.
Assessment of heterogeneity
It was planned that heterogeneity between study results would be
described and tested using the I2 statistic to ascertain whether it
reached statistical significance (Higgins 2003). Heterogeneity is
considered significant when the P value is less than 0.10 (Higgins
2011). As only one study was suitable for inclusion in the review,
assessment of heterogeneity was not necessary.
Assessment of reporting biases
If reporting bias was suspected (see ’Selective reporting bias’ in the
’Risk of bias’ table below), we planned to contact study authors
to ask them to provide missing outcome data. It was planned
that if missing data were not provided, and if this was thought to
introduce serious bias, the impact of including such studies in the
overall assessment would be explored through a sensitivity analysis.
As a single study with complete outcome reporting was included
in this review update, sensitivity analysis was not required.
Data synthesis
An initial qualitative comparison of all individually analysed stud-
ies was planned to examine whether pooling of results (meta-anal-
ysis) was reasonable. This comparison would have taken into ac-
count differences in study populations, inclusion/exclusion crite-
ria, interventions, outcome assessment and estimated effect size.
Results from studies that met the inclusion criteria and reported
any of the outcomes of interest would have been included in sub-
sequent meta-analyses. However, as only one study was suitable
for inclusion (based on study characteristics and inclusion crite-
ria of this review), a qualitative comparison of studies was not re-
quired. We created a ’Summary of findings’ table (SoF) (Summary
of findings for the main comparison) in accordance with methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Review of Interventions
(Higgins 2011) and using GRADEpro software.
The summary weighted odds ratio (OR) and 95% confidence
interval (95% CI) (fixed-effect model) were calculated using
RevMan. Numbers needed to treat for an additional beneficial
outcome (NNTB) were calculated from the pooled OR, and its
95% CI was applied to a specified baseline risk with use of an
online calculator (Cates 2003).
Subgroup analysis and investigation of heterogeneity
We had planned a priori subgroup analyses for children younger
than seven years of age and for those seven years of age and older.
As only a single study was identified for inclusion in the review,
subgroup analyses and investigations of heterogeneity were not
performed.
Sensitivity analysis
Sensitivity analyses were planned to assess the impact of potentially
important factors on overall outcomes.
1. Analysis by type of clinical pathway (e.g. continent-
specific).
2. Analysis by setting, whereby frequency of causes of chronic
cough may be different (e.g. general practitioners vs specialists,
affluent vs non-affluent countries, indigenous vs mainstream
communities).
3. Analysis using a random-effects model.
4. Analysis by “treatment received.”
5. Analysis by “intention-to-treat.”
As only a single study was included, subgroup (described above)
and sensitivity analyses were not performed.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
Combined searches (original and update reviews) performed by
the Cochrane Airways Group identified 727 potentially relevant
titles. After the abstracts were assessed, 10 studies were considered
for inclusion in the review, and one study (Chang 2013) fulfilled
the eligibility criteria of the review (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The sole study included in the reviewwas amulti-centre study sup-
ported by a competitive, non-commercial grant (National Health
and Medical Research Council of Australia). The study protocol
was published previously (Chang 2010). Study authors described
the trial as a pragmatic RCT (Chang 2013) utilising a standardised
clinical management pathway for management of chronic cough
in children (i.e. two weeks (early) vs six weeks (delayed) of re-
ferral by their referring physician). Children were randomly as-
signed by their referring physician to an early management path-
way (within three weeks of referral to the specialist practice) or
to usual care (i.e. later management with the pathway around the
six-week waiting period required to obtain a regularly scheduled
specialist appointment) (Chang 2013). The RCT did not strictly
explore intervention versus standard care (i.e. use vs non-use of
a clinical pathway), as all participants received the intervention
within the timing of the intervention (i.e. merely delayed). Study
authors justified the study design by stating that a cluster-blind
RCT would not be feasible, as all centres involved in the study
had similar standard clinical practices, in line with current rec-
ommendations (upon which the cough pathway was designed),
and physicians were not comfortable withholding treatment for
the purpose of a study. Similarly, the study authors acknowledged
that strict time point adherence (rather than “early” and “delayed”
use of the pathway) would introduce greater rigour to the study
but stated that a pragmatic design was required for the real-life
clinical settings in which the study operated (Chang 2013). This
study was conducted in paediatric hospital outpatient clinics at
five centres in Australia, and investigators recruited children who
were newly referred with chronic cough (lasting longer than four
weeks). A total of 272 participants were included in the study;
152 were male. The mean age of study participants was 4.5 (stan-
dard deviation (SD) 3.7) years, and the median duration of cough
at enrolment was 16 (interquartile range (IQR) 8 to 32) weeks
(Chang 2013).
Nineteen children were not treated according to the clinical path-
way, as they did not attend their first scheduled appointment with
the respiratory physician (n = 8 from the intervention group; n
= 11 from the control group). A further 22 children were with-
drawn from the study (parents withdrew n = 3; lost to follow-up
n = 17; protocol violation n = 1; non-adherence n = 1). Baseline
data for 253 participants were therefore available, as were complete
primary outcome data for 226 participants. Although the study
was undertaken to evaluate outcome measures four weeks post use
of the pathway in the early-pathway arm and before use of the
pathway in the delayed-pathway arm, participating children were
seen (hence the pathway was used) at 1.9 (SD 1) weeks and 5.1
(SD 1.8) weeks, respectively. Outcomes of the study were likely
diluted.
The study used proportions of cough-free (> 75% improvement in
cough or total resolution of cough for three ormore days according
to cough diary) children and parent-proxy quality of life score,
both measured at week six, as the primary outcome measures.
Excluded were children with a known chronic respiratory illness
(previously diagnosed by a respiratory physician or confirmed on
objective tests) such as cystic fibrosis or bronchiectasis.
For further details, see Characteristics of included studies.
Excluded studies
Nine studies were excluded (see Characteristics of excluded
studies) because they used a non-RCT design or did not use a
specific management protocol for cough treatment.
Risk of bias in included studies
Risk of bias in the included study is summarised in Figure 2 and
Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Assessed as low risk of bias. Study authors clearly described com-
puter-generated randomisation sequencing with concealed alloca-
tion.
Blinding
Assessed as low risk of bias. Although participants and research
personnel collecting data were not specifically informed about the
study arm to which they were allocated, the design of the study
made complete blinding not feasible. At the time the study was
conducted, the usual wait time to see a clinician in the public
health setting was used as the time frame for the delayed-pathway
arm (control) (i.e. around six weeks) and usual wait time for pri-
vate clinics was used as the time frame for the early-pathway arm
(intervention) (one to three weeks). Regarding the objective char-
acter of outcomemeasures, we did not expect high risk of bias with
clinical failure. With regards to subjective outcome measures, we
do not expect high risk of bias for parent-reported cough-specific
quality of life score (PC-QOL), as a standardised approach was
implemented for all study participants.
Incomplete outcome data
Assessed as low risk of bias. Study authors (Chang 2013) stated
that complete outcome data were obtained in more than 90% of
participants.
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Selective reporting
Assessed as low risk of bias, with study authors clearly describing
in the published manuscript the progress of all randomly assigned
participants. Limitations of the studywere identified and discussed
by the study authors.
Other potential sources of bias
The number of potentially eligible participants who were not en-
rolled (declined participation or were not approached for partici-
pation) is not stated by the study authors. This may introduce an
unclear assessment of recruitment selection bias.
Effects of interventions
See: Summary of findings for the main comparison
As only one study met the criteria for inclusion in this review,
no meta-analysis could be performed. The effects of intervention
presented below are reported by the single included study (Chang
2013).
Primary outcome
Proportions of participants who were not cured or were not
substantially improved at follow-up (clinical failure)
Intention-to-treat analysis revealed that clinical failure was signif-
icantly lower in the early-pathway arm (intervention) compared
with the delayed-pathway arm (control) (OR 0.35, 95% CI 0.21
to 0.58; Analysis 1.1), as presented in Figure 4. The control event
rate (i.e. the number of clinical failures reported from the con-
trol group) was 70.5% versus the intervention event rate of 46%
(Chang 2013). These results indicate that one child will be cured
for every five children treated by using the cough pathway at six
weeks (NNTB = 5, 95% CI 3 to 9; Cates plot, Figure 5).
Figure 4. Forest plot of comparison: 1. Primary outcome, outcome: 1.1. Clinical failure-primary outcome
(by intention-to-treat analysis).
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Figure 5. In the control group, 71 of 100 participants were not cured at follow-up over 6 weeks compared
with 46 of 100 (95% CI 33 to 58) for the active treatment group.
Secondary outcomes
Proportions of participants who were not cured at follow-up
The proportion of participants not cured at follow-up (secondary
outcome) is the same as the proportion of participants with clinical
failure (see primary outcome above) (Analysis 1.2).
Proportions of participants who were not substantially
improved at follow-up
The study reported only on participants cured or not cured at fol-
low-up. Participants not substantially improved were considered
not cured.
Mean differences in cough indices (cough diary, cough
frequency, cough-specific quality of life scores, cough
duration)
The parent-reported cough-specific quality of life score (PC-QOL)
at week six was significantly better (i.e. higher) for those in the
early-pathway arm compared with those in the delayed-pathway
arm (MD 0.60 points, 95% CI 0.19 to 1.01; Analysis 1.3).
Duration of cough post randomisation was significantly shorter
in the intervention group (early-pathway arm) compared with the
control group (delayed-pathway arm) (MD -2.70 weeks, 95% CI
-4.26 to -1.14; Analysis 1.4).
Proportions of participants experiencing adverse effects of
the intervention or complications
Study authors reported that none of the participants in the inter-
vention (pathway) group and none in the control (standard care)
group experienced adverse events.
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Other outcomes
Once the cough algorithm was used, irrespective of whether it was
applied early or was delayed, the duration of cough was similar.
Also, in contrast to results reported for a cough-specific quality of
life, no differences were noted between groups in terms of generic
health-related quality of life (PedsQL) score at six weeks (early
arm: median 92.5, IQR 81 to 96.5; delayed arm: median 87, IQR
76 to 96.3).
D I S C U S S I O N
Summary of main results
Only a single study fulfilled the inclusion criteria. This multi-cen-
tre study involved 272 children enrolled from hospital outpatient
departments in Australia. This body of evidence was graded as
moderate quality through the GRADE (Grades of Recommen-
dation, Assessment, Development and Evaluation) approach. An
ITT analysis revealed that clinical failure was significantly lower
in the early-pathway arm (clinical review within two weeks) com-
pared with the control arm (delayed use of pathway; clinical re-
view at six weeks) (OR 0.35, 95% CI 0.21 to 0.58). For the sec-
ondary outcome of mean score for cough-specific parent-reported
quality of life, the score was significantly better in the early-path-
way group (0.60 units, 95% CI 0.19 to 1.01) compared with the
control group. This is seen just at the minimum important differ-
ence (MID) (using the distribution method for calculating MID)
(Newcombe 2010; Newcombe 2010b). The intervention group
also had significantly shorter duration of cough post randomisa-
tion compared with the control group (MD -2.70, 95% CI -4.26
to -1.14). No adverse events were reported.
Overall completeness and applicability of
evidence
Clinical pathways are used for various chronic diseases to facilitate
diagnosis; aid decision making; and provide efficient care to pa-
tients. Chronic cough in children is a significant medical problem
that in some situations warrants thorough investigation. This re-
view is limited, as only data from a single study are available. Nev-
ertheless, data support the use of clinical management pathways
for chronic cough in children in a tertiary care setting.
Although the RCT in this review planned to compare outcomes
four weeks post use of the pathway in the early-pathway arm and
before use of the pathway in the delayed-pathway arm (i.e. within
six weeks of referral), pragmatically this was not feasible, and chil-
dren entered the protocol at times that were not strictly adhered
to, resulting in treatment of children by respiratory paediatricians
in accordance with the pathway at 1.9 (SD 1) weeks and 5.1 (SD
1.8) weeks, respectively. This flexibility in treatment time means
that study results are likely to be diluted, as children in the de-
layed-pathway arm received treatment before measurements were
undertaken.
Limitations
The algorithm applied in the included study was used by respira-
tory physicians (all but one person was a respiratory physician);
therefore, any effect that might be attributed to expertise required
to use the algorithm cannot be identified. However, steps within
the algorithm are simple and explicit, and most (85%) of the chil-
dren had diagnoses that could be made easily in primary care. For
example, key steps such as distinguishing between wet and dry
cough (Chang 2005b) and categorising specific versus non-spe-
cific cough (Marchant 2006b) are both feasible and reliable.
Thus, although the same pathway could be used in general prac-
tice, treatment outcomes may be different, as the pathway is de-
pendent on thorough history taking and examination (including
identifying the presence of crepitations). In general practice, agree-
ment of items in preschool children (most children with chronic
cough are of preschool age) such as wheeze and chest examination
findings has been shown to be poor (kappa values range from 0.12
to 0.39) (Hay 2004). Thus, applicability of the pathway (without
concurrent education) in general practice cannot be ascertained.
Further education for primary care providers on how to use the
algorithm is likely required for the algorithm to be as successful as
was reported in the included study.
A wait-list RCT pragmatic approach was used in the included
study. The design of this study is similar to the wait-list approach
used for some RCTs, such as those examining psychological inter-
ventions or paediatric surgery (e.g. tonsil-adenoidectomy for ob-
structive sleep apnoea), for which primary outcomes are selected
before the intervention is decided. Arguably, early versus delayed
use of the algorithm represents an alternative valid approach (c.f.
use vs non-use of an algorithm) that can be used to determine
whether the algorithm is efficacious, as effectively timing the pri-
mary outcome (at week six) tests use versus non-use of the algo-
rithm.
Quality of the evidence
Given that only one study could be included in this review, the
extent of the evidence is limited. Other than the unclear risk of
bias associated with blinding of participants, the risk of bias for
other criteria was low. This multi-centre study involved a rela-
tively large number of participants (i.e. for cough-related studies).
The consistency of favourable outcomes in the intervention arm
(including duration of cough post randomisation) supports the
unlikely presence of bias. Also, the generic quality of life measure
used (PedsQL), which is a less sensitive measure for cough, was
not significantly different between groups, but the cough-specific
quality of life score (PC-QOL) was significantly better in the early-
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pathway arm. Arguably, if quality of life was subject to clinically
important bias, PedsQL score would also be significantly better
in the intervention group (early-pathway arm) compared with the
control group (delayed-pathway arm).
In addition to significant differences between groups in primary
outcomes (PC-QOL and proportion ’cough-free’), the duration
of cough post randomisation was significantly different between
groups (early-pathway vs delayed-pathway groups). Cough dura-
tion at baseline (Table 1 in the included study) and post use of the
algorithmwas similar in the two groups. Thus, it is most likely that
use of the algorithm accounted for differences between groups.
Potential biases in the review process
Two of the authors of this review are co-authors of the sole RCT
that was included in this review. However, we took steps to reduce
bias by double-entering data, and the primary author of this review
was not involved in the included RCT.
Agreements and disagreements with other
studies or reviews
Data from cohort studies (Asilsoy 2008; Karabel 2013; Rehman
2009) are concordant with results of this review, which included
only RCTs. These cohort studies used a cough algorithm that is
similar to the one described in the included study. We are not
aware of any other systematic reviews with which these results can
be compared.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The limited available evidence presented here suggests that use of
management protocols in the diagnosis and treatment of children
with chronic cough (lasting longer than four weeks) is effective
in improving clinical outcomes (cough-free, shorter duration of
cough and improved parent-proxy cough-specific quality of life).
Implications for research
Further high-quality randomised controlled trials are needed for
ongoing evaluation of the use of clinical pathways for the manage-
ment of chronic cough in children. In these trials, settings should
include general practitioner and other primary care settings and
use of the cough algorithm should be compared with non-use of
the algorithm. A cluster-randomised trial design is likely the most
feasible study design in general practice. Use of validated cough
outcomemeasures is essential. The ascribed diagnostic criteria and
the definition of cough resolution should be decided a priori. Ide-
ally, an objective cough outcome (such as cough counts) should
also be included as an outcome.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chang 2013
Methods Randomised controlled trial
Participants Inclusion criteria: children (< 18 years of age) with chronic cough (> 4 weeks) newly
referred to specialist paediatric respiratory clinics at 5 Australian sites (Brisbane, Darwin,
Melbourne, Sydney, Canberra)
Exclusion criteria: children with known respiratory illness previously diagnosed by a
respiratory physician or confirmedonobjective testing (e.g. cystic fibrosis, bronchiectasis)
before the time of referral
Children assessed: n = 346 (n = 30 did not meet inclusion criteria, n = 44 declined
participation)
Children randomised: n = 272 (early use n = 140, delayed use n = 132)
Interventions 1. Early or delayed use of an algorithm for management of cough in children (2 vs 6
weeks of referral)
2. Children randomly assigned to the early intervention arm were seen by a
respiratory specialist and were managed according to the algorithm within 3 weeks of
referral and study enrolment
3. Children randomly assigned to the delayed intervention arm were seen by a
respiratory specialist and were managed according to the algorithm between 6 and 8
weeks of referral and study enrolment
Outcomes Primary outcomes:
1. Proportion of children who were cough-free (considered to be 75% improvement
in cough score, or total resolution for 3 consecutive days)
2. Quality of life measure (PC-QOL: cough-specific, parent-reported quality of life)
at week 6
Notes Because of the nature of the study, data collected up until the week 6 time point have
been selected for inclusion in this review, as this represents use (early arm) vs non-use
(delayed arm) of the algorithm. Information beyond week 6 of the study has not been
included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study authors refer to previously published trial proto-
col (Chang 2010): Study authors clearly describe com-
puter-generated randomisation sequence using permu-
tated blocks of 4 or 6, stratified according to participant
age and study site location
Allocation concealment (selection bias) Low risk Study authors state concealed allocation
18Clinical pathways for chronic cough in children (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chang 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Complete blinding was not possible. Participants and
research personnel collecting data were not specifically
informed about the arm to which they were allocated.
However, the allocated arm could easily be determined if
these individuals made the effort to look at time between
random assignment and clinical review
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study authors clearly describe (in previously published
protocol (Chang 2010)) outcomes measured by blinded
assessor and provide a description of how this was
achieved
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were measured in > 90% of par-
ticipants
Selective reporting (reporting bias) Low risk Progress of all randomly assigned participants was clearly
described
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Asilsoy 2008 Evaluation of chronic cough using American College of Chest Physicians (ACCP) guidelines. Excluded
from review, as not a randomised controlled trial (RCT)
Dettmar 2009 Study excluded, as not an RCT and not examining use of a management pathway. Study was a prospective
cohort study of an online diagnostic website for adult patients with chronic cough. The diagnostic website
allowed participants to provide information about their likely diagnosis that was based on a predetermined
algorithm, which differentiated among 3 common causes of chronic cough (reflux, asthma and rhinitis)
according to European Respiratory Society guidelines for chronic cough
English 2006 Study excluded, as not RCT and not examining use of a pathway for chronic cough. Study was a cross-
sectional evaluation of the accuracy of guidelines for screening patients for tuberculosis. Study found
that with implementation of clinical guidelines for nurse practitioner screening of patients for suspected
tuberculosis infection, a 68% increase in the rate of tuberculosis case detection was reported
Flores-Hernandez 1999 Study excluded, as not RCT and not examining use of a clinical pathway for chronic cough in children.
Before and after study of clinical guidelines for the management of acute respiratory infection, findings
show that after implementation of management guidelines, inappropriate prescribing of antibiotics and
cough syrups was decreased
Hover 2000 Study excluded, as not RCT and not examining chronic cough in children. Study was an evaluation
performed via pretreatment and post-treatment analysis and randomised chart review of implementation
of principles of the American Academy of Pediatrics for the management of common office infections.
Study did not utilise a clinical pathway and did not treat children with chronic cough
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(Continued)
Nagel 2009 Review article presenting diagnostic pathway and treatment options for chronic (> 4 weeks) cough in
children (published in German). Excluded, as not a research study. Paper presented a diagnostic and
management pathway similar to those presented by Chang 2013 and Rehman 2009, and reiterated that
cough lasting longer than 4 weeks in a child warrants thorough investigation for underlying pathology
Norton 2007 Prospective cohort study examining the effectiveness of a clinical pathway in reducing hospitalisation
for acute asthma episodes in children presenting to the emergency department of a children’s hospital.
Study showed that after the clinical pathway had been implemented, hospital admissions in children with
moderate to severe asthma were reduced by > 50% with no increase in re-presentations. Excluded, as not
RCT and pathway designed for acute asthma care, not chronic cough
Rehman 2009 This study was excluded, as it was not an RCT. This prospective cohort study of a management algorithm
for diagnosis of causes of chronic cough in children 6 to 59 months of age was specifically designed for
developing countries. Investigators aimed to establish the positive predictive value of the algorithm. This
study found that the positive predictive value of the algorithm in predicting clinical diagnosis was 0.921
Rutten 1991 RCT examining use of an educational programme (participant handout) on cough and effects on the
consulting behaviour of participants after they had received the intervention. Study excluded, as reported
participant numbers did not specify numbers of children included in the study. We contacted the study
author to obtain the numbers relevant for children; these data were not available. Study also excluded, as
the intervention used was not a clinical pathway, and the intervention was used for participants presenting
for acute cough episodes, not for chronic cough
Spelman 1991 Prospective cohort study examining the hypothesis that children with chronic cough will develop asthma.
106 participants with chronic cough, younger than 10 years of age, from Irish general practitioners, were
treated according to an asthma protocol for 16 weeks. Follow-up 2 years later showed that 71 children had
been subsequently diagnosed with asthma. Study excluded, as not RCT, and the protocol used was not
specific to the treatment of children with chronic cough
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D A T A A N D A N A L Y S E S
Comparison 1. Clincal pathway versus wait-list control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure-primary outcome 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Proportion of participants who
were not cured at follow-up
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 PC-QOL mean score at 6 weeks 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Duration of cough post
randomisation
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Proportion of adverse events
experienced
1 272 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Proportions of participants
experiencing adverse events or
complications
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Clincal pathway versus wait-list control, Outcome 1 Clinical failure-primary
outcome.
Review: Clinical pathways for chronic cough in children
Comparison: 1 Clincal pathway versus wait-list control
Outcome: 1 Clinical failure primary outcome
Study or subgroup Early use of pathway
Delayed use
of pathway Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chang 2013 64/140 93/132 0.35 [ 0.21, 0.58 ]
0.01 0.1 1 10 100
Favours early use Favours delayed use
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Analysis 1.2. Comparison 1 Clincal pathway versus wait-list control, Outcome 2 Proportion of participants
who were not cured at follow-up.
Review: Clinical pathways for chronic cough in children
Comparison: 1 Clincal pathway versus wait-list control
Outcome: 2 Proportion of participants who were not cured at follow-up
Study or subgroup Early use of pathway
Delayed use
of pathway Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chang 2013 64/140 93/132 0.35 [ 0.21, 0.58 ]
0.1 0.2 0.5 1 2 5 10
Favours early use Favours delayed use
Analysis 1.3. Comparison 1 Clincal pathway versus wait-list control, Outcome 3 PC-QOL mean score at 6
weeks.
Review: Clinical pathways for chronic cough in children
Comparison: 1 Clincal pathway versus wait-list control
Outcome: 3 PC-QOL mean score at 6 weeks
Study or subgroup Early use of pathway
Delayed use
of pathway
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chang 2013 123 5.61 (1.49) 103 5.01 (1.63) 0.60 [ 0.19, 1.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-4 -2 0 2 4
Favours delayed use Favours early use
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Analysis 1.4. Comparison 1 Clincal pathway versus wait-list control, Outcome 4 Duration of cough post
randomisation.
Review: Clinical pathways for chronic cough in children
Comparison: 1 Clincal pathway versus wait-list control
Outcome: 4 Duration of cough post randomisation
Study or subgroup Early use of pathway
Delayed use
of pathway
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chang 2013 123 6.4 (5.1) 103 9.1 (6.6) -2.70 [ -4.26, -1.14 ]
-10 -5 0 5 10
Favours early use Favours delayed use
Analysis 1.5. Comparison 1 Clincal pathway versus wait-list control, Outcome 5 Proportion of adverse
events experienced.
Review: Clinical pathways for chronic cough in children
Comparison: 1 Clincal pathway versus wait-list control
Outcome: 5 Proportion of adverse events experienced
Study or subgroup Early use of pathway
Delayed use
of pathway Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chang 2013 0/140 0/132 Not estimable
Total (95% CI) 140 132 Not estimable
Total events: 0 (Early use of pathway), 0 (Delayed use of pathway)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours early use Favours delayed use
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Analysis 1.6. Comparison 1 Clincal pathway versus wait-list control, Outcome 6 Proportions of participants
experiencing adverse events or complications.
Review: Clinical pathways for chronic cough in children
Comparison: 1 Clincal pathway versus wait-list control
Outcome: 6 Proportions of participants experiencing adverse events or complications
Study or subgroup Early use of pathway
Delayed use
of pathway Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chang 2013 0/140 0/132 Not estimable
0.01 0.1 1 10 100
Favours early use Favours delayed use
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL
#1 MeSH descriptor Cough explode all trees
#2 MeSH descriptor Bronchitis explode all trees
#3 cough* or bronchit*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Critical Pathways, this term only
#6 MeSH descriptor Clinical Protocols, this term only
#7 MeSH descriptor Guidelines, this term only
#8 MeSH descriptor Practice Guidelines, this term only
#9 (clinical path* or clinical guide* or critical path* or care map* or care path* or pathway*)
#10 (#5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Pediatrics explode all trees
#12 MeSH descriptor Child explode all trees
#13 MeSH descriptor Infant explode all trees
#14 MeSH descriptor Adolescent explode all trees
#15 child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young* or preschool* or “pre school*” or pre-school* or
newborn* or “new born*” or new-born* or neo-nat* or neonat*
#16 (#11 OR #12 OR #13 OR #14 OR #15)
#17 (#4 AND #10 AND #16)
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MEDLINE (Ovid)
1 exp COUGH/
2 exp BRONCHITIS/
3 (cough$ or bronchit$).
4 or/1-3
5 clinical pathways/ or Clinical Protocols/
6 guidelines/ or practice guidelines/
7 exp “guideline [publication type]”/
8 (clinical path$ or clinical guide$ or critical path$ or care map$ or care path$ or pathway$).mp.
9 or/5-8
10 adolescent/ or exp child/ or exp infant/
11 exp pediatrics/
12 (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
13 or/10-12
14 4 and 9 and 13
RCT filter
1. (controlled clinical trial or randomised controlled trial).pt.
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
EMBASE (Ovid)
1 exp COUGHING/
2 exp BRONCHITIS/
3 (cough$ or bronchit$).tw.
4 or/1-3
5 clinical pathway/
6 practice guideline/ or clinical pathway/ or clinical protocol/ or consensus development/ or good clinical practice/ or nursing care
plan/ or nursing protocol/
7 (clinical path$ or clinical guide$ or critical path$ or care map$ or care path$ or pathway$).mp.
8 or/5-7
9 exp adolescent/ or exp child/ or exp infant/ or exp newborn/
10 (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).tw.
11 exp pediatrics/
12 or/9-11
13 4 and 8 and 12
RCT filter
1. Randomized Controlled Trial/
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2. randomisation/
3. controlled clinical trial/
4. Double Blind Procedure/
5. Single Blind Procedure/
6. Crossover Procedure/
7. (clinica$ adj3 trial$).tw.
8. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind$ or method$)).tw.
9. exp Placebo/
10. placebo$.ti,ab.
11. random$.ti,ab.
12. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).tw.
13. (crossover$ or cross-over$).ti,ab.
14. or/1-13
15. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
16. human/ or normal human/ or human cell/
17. 15 and 16
18. 15 not 17
19. 14 not 18
Cochrane Airways Group Register of Trials (CAGR)
#1 MeSH DESCRIPTOR cough
#2 (cough*) AND (INREGISTER)
#3 COUGH:MISC1
#4 #1 OR #2 OR #3
#5 guideline* or pathway* or protocol*
#6 (care NEXT map*) or (care NEXT path*)
#7 #5 or #6
#8 #4 and #7
WH A T ’ S N E W
Last assessed as up-to-date: 8 January 2014.
Date Event Description
8 January 2014 New search has been performed Literature search updated
8 January 2014 New citation required and conclusions have changed One new study included; conclusions updated
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H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 2, 2008
Date Event Description
22 June 2009 New search has been performed Literature search rerun; no new studies found
22 July 2008 Amended Converted to new review format
1 February 2008 New citation required and conclusions have changed Substantive amendments made
C O N T R I B U T I O N S O F A U T H O R S
The first review was written primarily by EJB and ABC, who also reviewed the abstracts and articles. In this updated review, EJB and
ABC reviewed the searches from 2008 to 2012; GBM and ABC reviewed search data from 2012 to 2014. GBM and ABC extracted
and entered data for the 2014 update and drafted the review. All review authors approved the review before submission.
D E C L A R A T I O N S O F I N T E R E S T
ABC and PSM are authors of the included trial of a management protocol for the treatment of children with chronic cough. EJB was
involved in the early conduct of this trial (for the first year of the trial) but was not involved in development of the study protocol, data
analysis or manuscript production.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• National Health and Medical Research Council, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between the protocol and the review are described throughout the text. We updated the risk of bias tool and other methods
to bring the review in line with current recommendations provided in the Cochrane Handbook for Systematic Reviews of Interventions and
added a summary of findings table. We removed many of the sensitivity analyses specified in methods used previously for this review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Critical Pathways; Chronic Disease; Cough [∗therapy]
MeSH check words
Child; Humans
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